Download PDF

Leukemia & Lymphoma

Publication date: 2020-07-02
Volume: 61 Pages: 1885 - 1893
Publisher: Taylor & Francis

Author:

Goldman-Mazur, Sarah
Jurczyszyn, Artur ; Castillo, Jorge J ; Waszczuk-Gajda, Anna ; Grzasko, Norbert ; Radocha, Jakub ; Bittrich, Max ; Kortuem, Klaus Martin ; Gozzetti, Alessandro ; Usnarska-Zubkiewicz, Lidia ; Valls, Julio D ; Jayabalan, David S ; Niesvizky, Ruben ; Kelman, Julia ; Coriu, Daniel ; Rosinol, Laura ; Szukalski, Lukasz ; Gonzalez-Calle, Veronica ; Mateos, Maria-Victoria ; Jamroziak, Krzysztof ; Hus, Iwona ; Avivi, Irit ; Cohen, Yael ; Mazur, Piotr ; Suska, Anna ; Chappell, Aimee ; Madduri, Deepu ; Chhabra, Saurabh ; Kleman, Ariel ; Hari, Parameswaran ; Delforge, Michel ; Robak, Pawel ; Gentile, Massimo ; Kozlowska, Izabela ; Goldberg, Stuart L ; Czepiel, Jacek ; Dlugosz-Danecka, Monika ; Silbermann, Rebecca ; Olszewski, Adam J ; Barth, Peter ; Mikala, Gabor ; Chim, Chor S ; Vesole, David H

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Hematology, Translocation, t(14, 20), myeloma, survival, MAF, 16), INTERNATIONAL STAGING SYSTEM, THERAPY, FISH, t(14;16), t(14;20), Disease-Free Survival, Hematopoietic Stem Cell Transplantation, Humans, Multiple Myeloma, Prognosis, Retrospective Studies, Transplantation, Autologous, Treatment Outcome, 1103 Clinical Sciences, Immunology, 3201 Cardiovascular medicine and haematology

Abstract:

The MAF translocations, t(14;16) and t(14;20), are considered as adverse prognostic factors based on few studies with small sample sizes. We report on their prognostic impact in a large group of 254 patients - 223 (87.8%) with t(14;16) and 31 (12.2%) with t(14;20). There were no intergroup differences in survival estimates. Median progression-free survival was 16.6 months for t(14;16) and 24.9 months for t(14;20) (p = 0.28). Median overall survival (OS) was 54.0 months and 49.0 months, respectively (p = 0.62). Median OS in patients who underwent double autologous stem cell transplantation (ASCT) was 107.0 months versus 60.0 months in patients who received single ASCT (p < 0.001). ISS 3 was associated with shorter OS (HR = 1.89; 95% CI 1.24-3.19; p = 0.005) in Cox analysis. Our study suggests that t(14;20) should be considered as an adverse factor of equal prognostic implication to t(14;16).